LipAge Score v1.0 is a scoring system ranging from 0 to 100, developed to qualify cryopreserved autologous adipose tissue samples after thawing, based on criteria for morphology, cell viability, stromal vascular fraction preservation, complementary biological potential, and microbiological safety.
The system is in commercial use as a structured QA/QC tool. Important: it is not a clinically validated instrument with published outcome correlations — this status is communicated transparently.
| Domain 1 (25 pts) Morphology | Post-thaw morphological integrity of adipose tissue. Assessment using H&E at 10× and 40×. Criteria: preserved lobular structure, adipocytes with intact membranes, absence of extensive necrosis and disorganized fibrosis. |
| Domain 2 (25 pts) Cell Viability | Quantitative assessment using Trypan Blue and/or AO-PI. Acceptance criterion: viability ≥70%. Direct correlation with the functional potential of the thawed material. |
| Domain 3 (20 pts) SVF Preservation | Assessment of stromal vascular fraction (SVF) cells — pericytes, endothelial cells, ADSCs (CD34+/CD90+). Oil Red O for lipid visualization. Correlation with repair capacity (Gentile et al.: SVF increases retention from 39% to 63%). |
| Domain 4 (15 pts) Biological Potential | ⚠ v1.0 Note: Assessment of complementary biological potential. The measurement method for this domain is still in development in v1.0 — extracellular vesicle markers are not available as a routine assay. This domain is acknowledged as a placeholder until v2.0. |
| Domain 5 (15 pts) Microbiological Safety | Testing for bacterial and fungal contamination. A positive result = absolute rejection (Grade D), regardless of the other domains. No grading, no exceptions. |
| A+ (90–100) | Excellent-quality material — all domains at optimal levels. Released without restrictions for clinical use upon medical indication. |
| A (80–89) | High-quality material — approved for use. Minor variations in one or two secondary domains. |
| B (70–79) | Adequate-quality material — approved for use, with identified variations communicated to the requesting physician. |
| C (60–69) | Borderline-quality material — use at the physician's discretion, with detailed communication of the quality profile. The physician determines the indication. |
| D (<60 or microbiology+) | Absolute rejection. Material not released. Physician and patient notified. Includes any positive result in Domain 5, regardless of the total score. |
✅ It is: a structured QA/QC system with objective, reproducible criteria for qualifying and releasing cryopreserved samples.
✅ It is: an instrument in commercial use with 5 domains grounded in the biological evidence in the scientific literature.
❌ It is not: a clinically validated instrument with published correlations between Score and clinical outcome — this validation is a goal for v2.0 (2026–2027).
❌ It is not: a system with empirically calibrated domain weights — the current weights (25/25/20/15/15) are structurally defensible but have not been validated using internal data.
❌ Domain 4: acknowledged as a placeholder in v1.0 — the extracellular vesicle measurement method is not yet available as a routine assay.
v1.0 (current): Commercial use. Structured QA/QC system. Objective criteria and transparent communication.
v2.0 (target: November 2026–June 2027): Technical validation — inter-rater reliability for Domain 1; empirical calibration of weights; definition of internal MTT and Trypan Blue benchmarks; initial correlation with clinical outcomes.
v3.0 (target: 2028): Market authority — indexed publication, recognition as the category standard in Brazil.